No Association of VEGF Polymorphims with Alzheimer’s Disease
- 157 Downloads
The vascular hypothesis of Alzheimer’s disease (AD) has brought the vascular endothelial growth factor (VEGF) into focus. The genomic region including the VEGF gene has been linked to AD and single nucleotide polymorphisms (SNPs) of the VEGF have in previous studies been associated with AD risk. To further evaluate these findings, we genotyped two SNPs in the VEGF gene (rs699947 [−2578]) and rs1570360 [−1154]) by TaqMan Allelic Discrimination in a study sample including AD patients (n = 801) and controls (n = 286). In a subgroup of the population these SNPs were analyzed in relation to APOE ε4 genotype, to cerebrospinal fluid biomarkers (T-tau, P-tau, and β42-Amyloid) as well as to neuropathological markers for AD (neurofibrillary tangles and senile plaques). No significant associations with risk for AD or any of the studied biomarkers could be found in this study, thus not supporting VEGF as being a major risk gene for AD.
KeywordsAlzheimer’s disease VEGF Tau β-Amyloid
This work was supported by grants from the Swedish Research Council, the Swedish Society for Medical Research, the Sahlgrenska University Hospital, the Göteborg Medical Society, Swedish Brain Power, Hjalmar Svenssons forskningsfond, Stiftelsen för Gamla Tjänarinnor and Alzheimerfonden.
- Altman, D. G. (1991). Practical statistics for medical research (1st ed.). London: Chapman & Hall.Google Scholar
- Blennow, K., Ricksten, A., Prince, J. A., Brookes, A. J., Emahazion, T., Wasslavik, C., et al. (2000). No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer’s disease, and no change in A2M mRNA, protein, or protein expression. Journal of Neural Transmission, 107, 1065–1079.CrossRefPubMedGoogle Scholar
- McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939–944.PubMedGoogle Scholar
- Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjogren, M., et al. (2000). Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neuroscience Letters, 285, 49–52.CrossRefPubMedGoogle Scholar